CCCC · C4 Therapeutics Inc
United States · RS rating 70 · As of 2026-11-03
| Price | 3.21 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 70 / 77 / 43 / 70 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 36 / 38 / 53 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +59.1% |
| Sales growth Q/Q | -1.9% |
| Distance from 52-week high | +31.3% |
| Market cap (USD) | $289.8M |